关注第二十届亚太肝病学会年会

fromdesert34

Results: Interim data has shown that all patients treated to date have cleared
HBsAg and developed protective immunity. Clearance of HBsAg and
development of protective levels of anti-HBs occurred as early as 7 days following
initiation of treatment at higher doses.At the time of abstract submission,
one patient has already exhibited clear signs of a sustained virologic response
(HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) for 8 continuous
weeks off treatment after receiving only 23 weeks of treatment with REP9AC.
Conclusions: These results demonstrate that amphipathic polymers are effective
in rapidly reducing HBsAg levels in CHB patients which allows patients to
seroconvert. The rapid appearance of anti-HBs and anti-HBe antibodies in these
patients, the best predictors of SVR in patients with CHB, suggest that amphipathic
polymers could become an important new tool in the treatment of CHB.
======================================================

问下lemonades。。前面的内容已经他说了所有的病人已经清除了表抗原和产生表抗体了。。那为什么后面又说投稿前有一个已经产生持续性的病毒学应答？（乙肝病毒脱氧核糖核酸 - 乙肝表面抗原 - e抗原 - 抗- HBs +，抗- HBe +）到底是所有的都消除了表抗和产生抗体了还是就一个？

[ 本帖最后由 fromdesert34 于 2010-4-5 18:14 编辑 ]

11号宅男

原帖由 lemonades 于 2010-4-1 06:46 发表
Preliminary Evidence of Rapid HBsAg Seroconversion in Patients with
Chronic Hepatitis B (CHB) Treated with a DNA-based Amphipathic
Polymer
Mamun Al-Mahtab1, Michel Bazinet2, Andrew Vaillant2
1Bangaban ...

感觉这个内容挺重要的，我把内容翻译了一下，大家凑合着看：

背景：REP9AC是一种基于DNA的两亲性高聚物，其抗病毒作用与对病毒的进入及释放起重要作用的目标病毒蛋白糖有关。一种临床前试验——对持续感染鸭型乙肝病毒（DHBV）的鸭子采用28天REP 9AC治疗——表明能快速清除鸭型乙肝病毒的DNA、DHBsAg，并且能在停止REP 9AC治疗的16周后使50%的、从血液中测不出感染鸭型乙肝病毒的鸭子快速出现抗-DHB抗体。利用REP 9AC治疗乙肝病人的能力目前正通过“理论验证”试验予以评估。
方法：
缓慢持续使用REP9AC注射剂的方式对慢性乙肝病人进行治疗，每周对药物的安全性和病毒学应答（HBV DNA、HBsAg、抗-HBs标志）进行监测，监测场所既包括试验场所，也包括其他场所，在其他场所进行监测的方式为：利用ArchitectTM检测平台对冷冻血清样品做证实试验（HBsAg、HBeAg、抗-HBs、抗-HBe）。
结果：
临时性资料显示，截至今日，接受治疗的所有病人已清除HBsAg并出现保护性免疫。病人使用的剂量较高时，在开始使用该较高剂量的7天内，即会出现HBsAg清除效果并达到抗-HBs的保护性水平。在摘要提交之时，一名仅采用REP9AC治疗23周之后又撤药连续8周的病人体现出持续病毒学应答（(HBV DNA阴性, HBsAg阴性, HBeAg阴性, 抗-HBs 阳性, 抗-HBe阳性)）的明显特征。
结论：
以上结果表明，两亲性高聚物有快速降低乙肝病人的HBsAg水平的作用，可使病人出现血清学转换。这些病人的体内快速出现抗-HB和抗-HBe——乙肝病人对持续病毒学应答效果最有效的两个指标——表明两亲性高聚物可以成为治疗乙肝的一种新的、重要的工具。

声明：本人不对上述翻译（包括但不仅限于错译、误译）承担任何责任。

[ 本帖最后由 11号宅男 于 2010-4-5 22:05 编辑 ]

fromdesert34

原帖由 11号宅男 于 2010-4-5 21:50 发表


感觉这个内容挺重要的，我把内容翻译了一下，大家凑合着看：

背景：REP9AC是一种基于DNA的两亲性高聚物，其抗病毒作用与对病毒的进入及释放起重要作用的目标病毒蛋白糖有关。一种临床前试验——对持续感染鸭型乙肝病毒（DHBV） ...

越看越有疑问。。这篇文摘说REP9AC其中一例持续性应答也就8周到目前为止。。而另外一篇文章由shiweibuyi战友提供的却说所有的持续性应答有半年之久了（红色部分）。
Replicor will present results from its clinical proof of concept trial at the upcoming 20th annual meeting of the APASL in Beijing, China. This is the largest annual meeting dedicated to treatment of liver disease in Asia which typically attracts over 5,000 physicians and researchers. See: http://www.apasl2010beijing.org/en/index.aspx

Interim data on the efficacy of the amphipathic DNA polymer REP 9AC in the treatment of chronic hepatitis B in 6 patients will be presented. Interim results will show that REP 9AC treatment rapidly leads to the detection of anti-HBsAg antibodies and the reduction and or clearance of serum HBsAg within the first 12 weeks of treatment in human patients. These findings are associated with substantial and sustained reductions in serum HBV titers which may be due to an improved immune response to the infection. This is exemplified by the first patient who had 2,000,000 copies of the virus / ml in his blood, was then treated for a total of 23 weeks and who has so far maintained a sustained virologic response (<70 copies of the virus / ml in his blood) for a period of 6 months off treatment.
REP 9AC represents a new class of antiviral agent that blocks the release of HBsAg which has been associated with HBV-specific immune defects and may contribute to the long term persistence of the infection. It appears that REP 9AC effectively clears HBsAg in the serum and leads to the rapid acquisition of effective immunity against the infection.  REP 9AC may therefore provide an important new tool in the treatment of chronic hepatitis B.

11号宅男

文章的发布日期不一样吧，上面柠檬的那篇明确说了是“摘要提交之时”的结果。你说的那片文章是不是比柠檬的那篇后发表啊？因为看不到原文，连接又不够具体，所以无法确定时间。
当然，以上是我的猜测。

fromdesert34

原帖由 11号宅男 于 2010-4-5 22:15 发表
文章的发布日期不一样吧，上面柠檬的那篇明确说了是“摘要提交之时”的结果。你说的那片文章是不是比柠檬的那篇后发表啊？因为看不到原文，连接又不够具体，所以无法确定时间。
当然，以上是我的猜测。 ...

上面不是柠檬的文章。是另外一个战友提供的。。。柠檬那篇来自亚太会议上面的。

fromdesert34

我昨天发邮件询问了Michel Bazinet, MD此药物的具体信息。。今天就给回复了。回复如下。本人英文水平有限抱着试试的态度发的。没想到回了。大家给具体翻译下。


Thank you for your interest in our drug. We are still early in the clinical trial and cannot release much information yet. Our drug interacts with surface antigen (HBsAg) and prevents its release from infected hepatocytes. This results in a gradual reduction of surface antigen in the blood. Many scientific papers have suggested that surface antigen suppresses the immune response to the virus and allow the infection to be chronically maintained in the liver. By eliminating the surface antigen from the blood, it appears that we allow the immune system to mount an effective response against the virus and this can result in a clearance of the viral infection from the liver. In other words, by removing the surface antigen from the blood, we give the patient the ability to fight his hepatitis B infection on his own.

The interaction between our drug and surface antigen occurs over a large surface area.  Therefore, resistance to the drug will be very unlikely.

It is too early to comment on side effects since we have treated only a few patients but it appears that the drug will be much easier to tolerate than interferon.

We do not have approval to do a clinical study in China at this time.

We are trying to go as fast as possible to bring this drug to patients but it will likely take a few years before it is approved and available for use. We are currently trying to raise funds to accelerate the recruitment of patients in our clinical trial.

The best way you can understand the potential of our drug is by understanding the importance of surface antigen in suppressing the ability of the immune response to fight the infection. I have listed below some of the scientific references that discuss this topic (many of these papers were published by Chinese scientists). These papers are very technical in nature but there might be scientists in your group that can understand them.

Best regards.

肝胆相照009

Thank you for your interest in REPLICor’s hepatitis B drug.

Please checkout our latest press release on our progress in developing our technology for the treatment of hepatitis B here: http://www.replicor.com/debut_anglais2.htm and select “News”.

The press release provides an up to date summary of how patients are progressing on the REP 9AC treatment.

Regards,
________________________________
Andrew Vaillant, Ph.D.
Vice President and CSO
REPLICor Inc.
6100 Royalmount Avenue, Suite D-101
Montreal  Quebec  Canada H4P 2R2
[email protected]
(514) 496-9011 (office)
(514) 496-9021 (fax)
(514) 862-2271 (mobile)
This message and any attachments are confidential and for the intended recipients only.

fromdesert34

大家帮忙想想怎么用英文问他我上面问的问题啊。。我的英文水平不够好。。。

问题如下：

Results: Interim data has shown that all patients treated to date have cleared
HBsAg and developed protective immunity. Clearance of HBsAg and
development of protective levels of anti-HBs occurred as early as 7 days following
initiation of treatment at higher doses.At the time of abstract submission,
one patient has already exhibited clear signs of a sustained virologic response
(HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) for 8 continuous
weeks off treatment after receiving only 23 weeks of treatment with REP9AC.
Conclusions: These results demonstrate that amphipathic polymers are effective
in rapidly reducing HBsAg levels in CHB patients which allows patients to
seroconvert. The rapid appearance of anti-HBs and anti-HBe antibodies in these
patients, the best predictors of SVR in patients with CHB, suggest that amphipathic
polymers could become an important new tool in the treatment of CHB.
======================================================

前面的内容已经他说了所有的病人已经清除了表抗原和产生表抗体了。。那为什么后面又说投稿前有一个已经产生持续性的病毒学应答？（乙肝病毒脱氧核糖核酸 - 乙肝表面抗原 - e抗原 - 抗- HBs +，抗- HBe +）到底是所有的都消除了表抗和产生抗体了还是就一个？
问题二：

有一篇文章中写到了所有病人的持续性应答都已经达到半年了而在apasl上发布的却只有8周？

[ 本帖最后由 fromdesert34 于 2010-4-6 11:48 编辑 ]

别愁

原帖由 fromdesert34 于 2010-4-6 10:54 发表
我昨天发邮件询问了Michel Bazinet, MD此药物的具体信息。。今天就给回复了。回复如下。本人英文水平有限抱着试试的态度发的。没想到回了。大家给具体翻译下。


Thank you for your interest in our drug. We are s ...

大意：
治疗原理：通过阻止表面抗原从受感染的肝细胞释放到血液中，逐渐减少其在血液中的含量，从而加强人体自身清除病毒的能力。（因为HBsAg 会压制免疫系统对病毒的清除作用，从而导致感染慢性化）
副作用：因试验人数少，目前无法确定，但比干扰素耐受性要好的多。
临床及上市：需几年，现需筹集资金加快招募试验人员。

[ 本帖最后由 别愁 于 2010-4-6 11:58 编辑 ]

fromdesert34

原帖由 别愁 于 2010-4-6 11:45 发表

大意：
原理：通过压制表面抗原从肝细胞释放到血液中，减少其含量，从而加强人体自身清除病毒的能力。
副作用：因试验人数少，无法确定，但比干扰素耐受性要好的多。
临床及上市：需几年，需募集资金招募试验人员。 ...

谢谢你啊。。能否帮我译下我上面的问题。。我想了半天都不知道如何表述。。